How It Compares to Wegovy

  • Supreme Court Casts Doubt on Trump Birthright Citizenship Order

    01:55

  • Young Boy’s Birthday Surprise of WWE Tickets Brings Him to Tears

    01:03

  • Now Playing

    FDA Approves Eli Lilly’s New Weight Loss Pill Foundayo

    03:12

  • UP NEXT

    Hawaii Doctor Takes the Stand in Attempted Murder Trial

    02:19

  • Tiger Woods Granted Permission to Leave US for Treatment

    00:27

  • Trump Vows to Hit Iran ‘Extremely Hard’ in Coming Weeks

    05:50

  • Artemis II Roars Into Space in Groundbreaking Moon Mission

    05:37

  • Hershey’s to Return to Pure Chocolate Ingredients in All Recipes

    00:32

  • Influencer Shines Light on Struggling Family-Owned Restaurant

    04:56

  • Get an Inside Look at How Fiesta Tableware Products Are Made

    05:00

  • More Americans Are Taking on Side Hustles to Make Extra Cash

    04:06

  • Why Las Vegas Hotels Are Rolling the Dice on All-Inclusive Options

    03:10

  • A Look Back at Apple’s History and Impact as It Marks 50 Years

    05:40

  • Trump to Attend Supreme Court Birthright Citizenship Hearing

    01:50

  • Son of Hawaii Doctor Accused of Trying to Kill Wife Testifies in Trial

    00:45

  • Hegseth Lifts Suspension of Crew Who Flew by Kid Rock’s Home

    00:29

  • Judge Halts Construction on Trump White House Ballroom Project

    00:41

  • 8-Year-Old Gets Warmest Welcome From Her Class After Surgery

    00:50

  • Tiger Woods Breaks His Silence Following DUI Arrest in Florida

    02:51

  • Trump Says War With Iran Will End Soon Even as Attacks Escalate

    02:10

The Food and Drug Administration on Wednesday approved Eli Lilly’s new GLP-1 daily pill called Foundayo. It’s a new option for the millions looking to try weight loss drugs without having to use a needle and it’s set to hit the market next week. It follows the approval of Novo Nordisk’s Wegovy pill in December. NBC’s Anne Thompson reports for TODAY.


Source: Read Full Article

Sam Miller

Leave a Reply

Your email address will not be published. Required fields are marked *